论文部分内容阅读
目的:在一项大范围试验中评估氯氮平(Clozapine)对住院难治性精神分裂症患者的症状改善和副作用.方法:由一个大规模的州公共精神病学系统组成.方案要求精神科专科医生在药物治疗开始后进行4次症状和副作用的评定.治疗效果的评估标准包括症状改善的Sandoz研究评估标准以及出院后随访一年的情况.同时确定了控制评定一致性的几个措施,以保证结果评估的真实性.接受氯氮平治疗的患者共227例,而可获得症状资料的有202例.结果:总体上,在一年治疗结束时有33%病人(n=66)症状获得改善,12%的病人(n=24)在3次评定时症状持续改善.至少在152例持续服药的患者中,于治疗12W后观察到简明精神病评定量表(BPRS)评分比用药前比较有显著的统计学意义.而既往治疗无效的病例(n=26)的好转也说明了该药的治疗效果.然而,对整个202例(包括退出者)的分析显示,12w后患者的病情并无显著的改善.在那些用药治疗一年的病人中,对
PURPOSE: To evaluate the improvement of symptoms and side effects of Clozapine in hospitalized patients with refractory schizophrenia in a large-scale trial.Methods: A large-scale state public psychiatric system comprised of a program called Psychiatry The physician assessed the symptoms and side effects four times after the start of the drug treatment.The evaluation criteria for the treatment effect included the Sandoz criteria for evaluation of the symptoms and the year-to-year follow-up of discharge and several measures to control the consistency of the assessment To ensure the authenticity of the outcome assessment, 227 patients were treated with clozapine and 202 with available symptom data.Results: Overall, 33% of patients (n = 66) achieved symptoms at the end of the one-year treatment Improved in 12% of patients (n = 24) with a continuous improvement in symptoms at three assessments. Conclusions of the Simplified Mental Disorder Rating Scale (BPRS) were observed at least 12 weeks after 12 weeks of treatment in at least 152 consecutive patients Significant statistical significance, and the improvement of previous treatment ineffective cases (n = 26) also demonstrated the therapeutic effect of the drug.However, the analysis of the entire 202 cases (including the withdrawal) showed that after 12 weeks, the patient’s condition did not Significantly Of those who had been on medication for a year, yes